[go: up one dir, main page]

DK2705013T3 - Pentylenetetrazolderivater - Google Patents

Pentylenetetrazolderivater Download PDF

Info

Publication number
DK2705013T3
DK2705013T3 DK12724430.9T DK12724430T DK2705013T3 DK 2705013 T3 DK2705013 T3 DK 2705013T3 DK 12724430 T DK12724430 T DK 12724430T DK 2705013 T3 DK2705013 T3 DK 2705013T3
Authority
DK
Denmark
Prior art keywords
compound
deuterium
ptz
pharmaceutically acceptable
hydrogen
Prior art date
Application number
DK12724430.9T
Other languages
English (en)
Inventor
Lyndon Lien
Original Assignee
Balance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balance Therapeutics Inc filed Critical Balance Therapeutics Inc
Application granted granted Critical
Publication of DK2705013T3 publication Critical patent/DK2705013T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (6)

1 ormel I:
w eller et farmaceutisk acceptabelt salt deraf, hvor: hvert af R1, R2, R3, R4, R5, R6, R7, R8, R9 og R10 uafhængigt er udvalgt blandt hydrogen og deuterium, hvor mindst et af R1, R2, R3, R4, R5, R6, R7, R8, R9 og R10 ikke er hydrogen, og hvor, når hvert af R1, R2, R9 og R10 er hydrogen, så er mindst et af R3, R4, R5, R6, R7 og R8 andet end deuterium, og hvor en position, som er betegnet som "D" eller deuterium, hvilken position forstås at have deuterium i en forekomst, der er mindst 3.340 gange større end den naturlige forekomst af deuterium.
2. Forbindelse ifølge krav 1, eller farmaceutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt fra gruppen bestående af
3. Farmaceutisk sammensætning omfattende forbindelsen ifølge et hvilket som helst af kravene 1-2, eller farmaceutisk acceptabelt salt deraf, og et farmaceutisk acceptabelt hjælpestof.
4. Enhedsdosisform omfattende 0,1 mg til 1 g af forbindelsen ifølge krav 1, eller farmaceutisk acceptabelt salt deraf, og et eller flere farmaceutisk acceptable hjælpestoffer, hvor enhedsdoseringsformen er velegnet til oral eller intravenøs indgivelse til et menneske. 2
5. Forbindelse ifølge krav 1 til anvendelse som et kredsløbs- eller luftvejsstimulerende middel; eller til anvendelse som hostemedicin; eller til anvendelse til behandling af senilitet, senil konfusion, psykoser, psy-koneuroser, når angst og nervøs anspændthed er til stede, cerebral arterio-sklerose, kvalme, depression, træthed, afkræftelse, mild adfærdsforstyrrelse, irritabilitet, labilitet, antisocial attitude, angst, svimmelhed eller inkontinens eller symptom derpå.
6. Forbindelse ifølge krav 1, til anvendelse til forbedring af kognitiv funktion hos en person med Downs syndrom, fenylketonuri, neurofibromatose type 1, ahornsirupurinsygdom, Retts syndrom, føtalt alkoholsyndrom, en autisme-spektrumforstyrrelse, døgnrytmeforstyrrelse, Alzheimers sygdom eller demens.
DK12724430.9T 2011-05-04 2012-05-03 Pentylenetetrazolderivater DK2705013T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482533P 2011-05-04 2011-05-04
PCT/US2012/036217 WO2012151343A1 (en) 2011-05-04 2012-05-03 Pentylenetetrazole derivatives

Publications (1)

Publication Number Publication Date
DK2705013T3 true DK2705013T3 (da) 2016-07-18

Family

ID=46178772

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12724430.9T DK2705013T3 (da) 2011-05-04 2012-05-03 Pentylenetetrazolderivater

Country Status (13)

Country Link
US (2) US9453020B2 (da)
EP (1) EP2705013B1 (da)
JP (3) JP6092849B2 (da)
CN (1) CN103635446B (da)
AU (3) AU2012250776B2 (da)
CA (1) CA2835018C (da)
DK (1) DK2705013T3 (da)
ES (1) ES2579319T3 (da)
HK (1) HK1195050A1 (da)
IL (2) IL229218A (da)
MX (1) MX362218B (da)
WO (1) WO2012151343A1 (da)
ZA (1) ZA201408423B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151343A1 (en) * 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
WO2015160766A1 (en) 2014-04-15 2015-10-22 Balance Therapeutics, Inc. Methods for treating hypersomnia
WO2018209119A1 (en) 2017-05-10 2018-11-15 Emory University Treatment of conditions associated with myotonic dystrophy
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
CN112920193B (zh) * 2021-02-07 2021-11-16 南通大学 一种灰黄霉素四唑衍生物及其制备方法
CN112979665B (zh) * 2021-02-07 2021-11-19 南通大学 一种灰黄霉素施密特重排衍生物及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062720A (en) 1959-05-20 1962-11-06 Philips Roxane Sustained release pharmaceutical tablet
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4663308A (en) 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (da) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SK74495A3 (en) 1993-01-06 1997-01-08 Kinerton Ltd Ionic molecular conjugates of biodegradable polyesters with bioactive polypeptides and a method of preparation thereof
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69535592T2 (de) * 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
DK0895517T3 (da) 1996-04-23 2005-01-17 Ipsen Mfg Ireland Ltd Sure polymælkesyrepolymerer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
JP2002541092A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
EP1194128A2 (en) 1999-06-23 2002-04-10 Sedum Laboratories Ionically formulated biomolecule microcarriers
DE60027334T2 (de) 1999-08-18 2007-03-29 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
WO2002058672A2 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
EP1383376A4 (en) 2001-03-19 2006-03-08 Praecis Pharm Inc PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
KR20040091100A (ko) 2002-03-04 2004-10-27 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 운반체 펩타이드를 함유하는 서방형 의약 조성물
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
CA2935516A1 (en) * 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
BRPI0714484A2 (pt) * 2006-08-16 2013-04-24 Auspex Pharmaceuticals Inc composto, mÉtodo de tratar um mamÍfero sofrendo de uma doenÇa ou condiÇço, mÉtodo de tratar um memÍfero sofrendo de uma doenÇa, desordem, sintoma ou condiÇço e composiÇço farmacÊutica
US8946206B2 (en) 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
WO2012151343A1 (en) * 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives

Also Published As

Publication number Publication date
AU2017219099A1 (en) 2017-09-14
JP2014513130A (ja) 2014-05-29
US20140343040A1 (en) 2014-11-20
AU2017219099B2 (en) 2019-05-30
ES2579319T3 (es) 2016-08-09
US9453020B2 (en) 2016-09-27
AU2012250776B2 (en) 2017-06-15
EP2705013A1 (en) 2014-03-12
HK1195050A1 (zh) 2014-10-31
CA2835018A1 (en) 2012-11-08
JP2019006819A (ja) 2019-01-17
EP2705013B1 (en) 2016-03-30
CN103635446A (zh) 2014-03-12
JP6092849B2 (ja) 2017-03-08
JP2017105821A (ja) 2017-06-15
CA2835018C (en) 2020-04-21
IL248589A (en) 2017-09-28
CN103635446B (zh) 2016-02-03
MX362218B (es) 2019-01-09
US20170044165A1 (en) 2017-02-16
AU2019213325A1 (en) 2019-08-22
IL229218A0 (en) 2014-01-30
US9951076B2 (en) 2018-04-24
NZ617347A (en) 2015-11-27
IL248589A0 (en) 2016-12-29
IL229218A (en) 2016-11-30
AU2012250776A1 (en) 2013-12-05
MX2013012850A (es) 2014-04-30
WO2012151343A1 (en) 2012-11-08
ZA201408423B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
AU2017219099B2 (en) Pentylenetetrazole derivatives
DK2328414T3 (da) Substituerede triazolopyridazinderivater
US10463753B2 (en) Radiolabeled monoacylglycerol lipase occupancy probe
US20060025418A1 (en) Methods of making and using N-desmethylzopiclone
JP6990702B2 (ja) 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体
US8357674B2 (en) Analogues of cilostazol
US12043605B2 (en) Deuterated empathogens
JP2024540583A (ja) Ｋｖ７．２エンハンサーとしてのピリジン化合物
CA3230779A1 (en) Asymmetric allyl tryptamines
NZ617347B2 (en) Pentylenetetrazole derivatives
WO2023028092A2 (en) Fluorinated empathogens
WO2019046534A1 (en) INDOLOQUINOLINE COMPOUNDS DEUTTERED
JP2014506603A (ja) ２−アミノ−ナフチリジン誘導体
CA2824626A1 (en) 2-amino-naphthyridine derivatives